To date, the main clinical practice, screening for NPC, is to detect the presence of Epstein–Barr virus (EBV), one of the etiological factors, via the detection of EBV DNA, EBV-VCA-IgA, EBNA1-IgA, and Rta-IgG [4,5,6]. The gene discussed is CD79A; the disease is nasopharyngeal carcinoma.